Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 22, Issue 1, 1997, Pages 65-72

  Toft, K G ^a   Hustvedt, S O ^a   Grant, D ^a   Friisk, G A ^a   Skotland, T ^a  

^a NYCOMED IMAGING AS   (Norway)

Author keywords

Contrast media; Dephosphorylation; Dog; HPLC; Mangafodipir trisodium; Manganese; MnDPDP; Transmetallation

Indexed keywords

CONTRAST MEDIUM; MANGAFODIPIR; MANGANESE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ZINC;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPHOSPHORYLATION; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SEX DIFFERENCE;

EID: 0030966461     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189786     Document Type: Article

References (16)

1. Normann P.T., Hals P-A. (1996): In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging. Eur. J. Drug Metab. Pharmacokinet., 20, 307-313.
2. Weinmann H.J., Laniado M., Mutzel W. (1984): Pharmacokinetics of Gd-DTPA dimeglumine after intravenous injection into healthy volunteers. Physiol. Chem. Phys., 16, 167-172.
3. McLachlan S.J., Eaton S., Desimone D.N. (1992): Pharmacokinetic behavior of gadoteridol injection. Invest. Radiol., 27 (suppl. 1), 12-15.
4. Elizondo G., Fretz C.J., Stark D.D. et al. (1991): Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology, 178, 73-78.
5. Lim K.O., Stark D.D., Leese P.T., Pfefferbaum A., Rocklage S.M., Quay S.C. (1991): Hepatobiliary MR imaging: first human experience with MnDPDP. Radiology, 178, 79-82.
6. Rocklage S.M., Cacheris W.P., Quay S.C., Hahn F.E., Raymond K.M. (1989): Manganese(II) N,N′-dipyridoxylethylenediamine-N,N′-diacetate 5,5′-bis(phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg. Chem., 28, 477-485.
7. Rofsky N.M., Weinreb J.C., Bernardino M.E., Young S.W., Lee J.K.T., Noz M.E. (1993): Hepatocellular tumours: characterization with MnDPDP - enhanced MR imaging. Radiology, 188, 53-59.
8. 1 response to manganese injection in the dog and rabbit. Am. J. Radiol., 141, 193-197.
9. Jynge P., Brurok H., Asplund A. et al. (1995): Cardiovascular safety of MnDPDP: experience from ex vivo and in vivo animal experiments. In: Rinck P.A., Muller R.N. (Eds) New Developments in Contrast Agent Research. Mons, Belgium: Eur. Magn. Reson. Forum, 83-103.
10. Toft K.G., Kindberg G.M., Skotland T. (1997): Mangafodipir trisodium, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies in human blood. J. Pharm. Biomed. Anal., In press.
11. Grant D., Zech K., Holtz E. (1994): Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy. Invest. Radiol., 29 (suppl. 2), S249-S250.
12. Toft K.G., Friisk G.A., Skotland T. (1997): Mangafodipir trisodium, a new contrast medium for magnetic resonance imaging: detection and quantitation of the active compound and metabolites in human plasma by high performance liquid chromatography. J. Pharm. Biomed. Anal., In press.
13. 2-macroglobulin from human serum. Biochemistry, 9, 2421-2426.
14. Normann P.T., Hustvedt S.O., Storflor H., Hals P-A. (1995): Preclinical safety and pharmacokinetic profile of gadodiamide injection. Clin. MRI, 5, 95-101.
15. Okazaki O., Kurata T., Yoshioka N., Hakusui H. (1996): Pharmacokinetics and stability of caldiamide sodium in rats. Arzneimittelforschung., 46, 79-83.
16. Toft K.G., Hustvedt S.O., Grant D. et al. (1997): Metabolism and pharmacokinetics of mangafodipir trisodium (MnDPDP) in man. Acta Radiol., In press.